NCCN releases first guidelines for pediatric ALL

  • NCCN
  • NCCN
  • 30 May 2019

  • Oncology guidelines update
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Novel guidelines from the National Comprehensive Cancer Network (NCCN) on pediatric acute lymphoblastic leukemia (ALL) place strong emphasis on supportive care interventions for reduction of severe adverse effects and incorporate a number of novel regimens.

Why this matters

  • Advances including targeted therapy, immunotherapy, and the approval of chimeric antigen receptor (CAR) T-cell therapy have increased cure rate to approximately 90%, reducing the number of patients in clinical trials.
  • NCCN guidelines have increasingly attained global reach.

Key recommendations

  • Supportive care interventions have been given greater focus to reduce burden of severe adverse effects during treatment, as well as late effects.
  • The new guidelines provide advice on best supportive care in vulnerable subpopulations such as very young infants and children with Down syndrome.
  • A number of novel treatment strategies have been included such as targeted therapies and CAR T-cell therapy.
  • The new guidelines have been designed to span patient ages from birth through young adulthood, and to overlap with guidelines for adults, fostering treatment harmonization in the overlapping age range.
  • In response to the increasing global reach of these guidelines, future revisions will also cover best practices applicable in low- and middle-income countries.